Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

Pharming Healthcare

Status and phase: Withdrawn; Phase 2

Conditions: Kidney Transplantation; Graft Rejection

Treatments: Drug: recombinant C1 inhibitor; Procedure: plasmapheresis and IVIG

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01035593

C1 2201

Details and patient eligibility

About

The purpose of this study will be to assess the safety, tolerability, and efficacy of rhC1INH in renal transplant recipients with biopsy-confirmed antibody-mediated rejection (AMR) within 30 days of renal transplantation. This study will combine the investigational drug rhC1INH with a standard regimen of plasmapheresis (PP) and intravenous immune globulin (IVIG) and compare this to PP and IVIG alone.

Full description

This is an Investigator-initiated, prospective, open-label, randomized, adaptive design study to enroll 30 adult renal transplant recipients with biopsy-confirmed AMR within 30 days post transplantation. After informed consent is obtained and study eligibility is confirmed, subjects will be enrolled immediately after biopsy confirmation of AMR and positive donor specific antibody (DSA). Subjects will then be randomized into one of two treatment groups (SOC [control] or rhC1INH). An initial cohort of 8 subjects (3 SOC, 5 rhC1INH) will receive intensive safety monitoring of the coagulation system and for thromboembolic events.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recipients of renal transplantation within 30 days prior to enrollment.
• AMR documented by light microscopic changes and immunohistochemical C4d staining on renal biopsy within 30 days post-transplant.
• Positive DSA as detected by magnetic microbeads using a Luminex® system.
• Age ≥ 18 years.
• Women of child-bearing potential (CBP) must have negative pregnancy test at screening.
• Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the study and for 3 months following discontinuation of assigned treatment.
• Subjects must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.

Exclusion criteria

• Recipients of multi-organ transplants.
• Recipients with previous early AMR.
• Recipients with a known hypersensitivity to C1INH, rabbit anti-thymocyte globulin, or any rabbit protein.
• History of malignancy within 3 years of enrollment (except for adequately treated basal cell or squamous cell carcinoma of the skin).
• Subjects who are positive for hepatitis C, hepatitis B surface antigen, or HIV at the time of transplant.
• Subjects who are actively taking an investigational drug.
• Subjects with a history of a psychological illness or condition that could interfere with the subject's ability to understand the requirements of the study.
• Female subjects who are pregnant or nursing.
• Subjects with hemodynamic instability, as defined by a mean arterial pressure (MAP) <60 mmHg or >110 mmHg; or requirement of vasopressors to maintain a MAP of 60 mmHg; or requirement of IV vasodilators for hypertensive emergency; or acute pulmonary edema.
• Subjects with known active infection at the time of enrollment.
• Biopsy-confirmed concurrent cellular rejection requiring polyclonal antibody therapy (i.e., all Grades other than Banff 1a and 1b will be excluded).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Standard of Care (PP + IVIG)

Active Comparator group

Description:

Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments

Treatment:

Procedure: plasmapheresis and IVIG

PP + IVIG + rhC1INH

Experimental group

Description:

Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).

Treatment:

Drug: recombinant C1 inhibitor